Skip to content

Study on the correlation between different phenotypes and molecular characteristics in female pattern hair loss patients

Study on the correlation between different phenotypes and molecular characteristics in female androgenetic alopecia patients

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300074901
Enrollment
Unknown
Registered
2023-08-18
Start date
2023-08-17
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

female pattern hair loss

Interventions

type A alopecia patients group(Diffuse thinning of the crown region with preservation of the frontal hairline):None
type B alopecia patients group(Frontal hair thinning accentuation resulting in the “Christmas tree” pattern):None
type C alopecia patients group(Bitemporal recession could be observed, rarely it could be associated with vertex thinning, looks like male androgenetic alopecia):None

Sponsors

Beijing Friendship Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: FAGA patients: (1) Outpatient female alopecia patients aged 18-45 years old; (2) Screening patients who meet FAGA diagnosis by inquiring about medical history, clinical manifestations, hair microscope, endocrine testing, etc; (3) Informed consent to participate in this project. Healthy volunteers: (1) Female aged 18-45 years old; (2) Healthy hair and scalp, without hair loss; (3) Informed consent to participate in this project.

Exclusion criteria

Exclusion criteria: (1) Pregnant or lactating women; Menopausal women; Women with menstrual disorders; (2) Other types of hair loss, such as alopecia areata, hair loss during rest period, and hair loss caused by tinea capitis; (3) Circumstances such as scalp inflammation and trauma that are not suitable for collecting hair follicles; (4) Accompanied by other serious diseases such as infections, tumors, and psychiatric symptoms; (5) Participating in other clinical trials; (6) The investigator considers it inappropriate to participate in the study.

Design outcomes

Primary

MeasureTime frame
RNA-seq;

Countries

China

Contacts

Public ContactZhuo Fenglin

Beijing Friendship Hospital, Capital Medical University

770972657@qq.com+86 159 1089 5068

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026